Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals [5]

Clinical Infectious Diseases

Volumn 42, Issue 11, 2006, Pages 1656-1657

  Lanzafame, Massimiliano ^a,b   Lattuada, Emanuela ^a   Rapagna, Francesca ^a   Gottardi, Martina ^a   Vento, Sandro ^a  

^a Policlinico GB Rossi   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADULT; DRUG ACCUMULATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY PROXIMAL TUBULE; LETTER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTPATIENT DEPARTMENT; PHOSPHORYLATION; PRIORITY JOURNAL; RISK FACTOR;

ADENINE; ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 33646719502     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504089     Document Type: Letter

References (10)

1. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-90.
2. Cheng A, Cheng SS, Wulfsohn M, et al. 2 Year long term safety profile of tenofovir DF in treatment-experienced patients from randomized, double-blind, placebo-controlled clinical trials [abstract 7.3/7]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw). Paris: European AIDS Clinical Society, 2003.
3. Staszewski S, Gallant JE, Pozniak AL, et al. Three-year analysis of the renal safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral- naïve patients [poster 5917]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.
4. Parish MA, Gallant JE, Moore R. Changes in renal function in patients treated with tenofovir DF vs nucleoside reverse transcriptase inhibitors [poster 751]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
5. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case control study. JAIDS 2004; 37:1489-95.
6. Scott J, Wolfe P, Quiros J, et al. Rare occurrence of renal impairment when retrospectively evaluating the use of TDF in two clinical practices [poster 4632]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.
7. Gallais H, Lazzarin A, Adam A, et al. The Viread expanded access program (EAP) in Europe/Australia: summary of the safety and efficacy of tenofovir disoproxil fumarate (TDF) in antiretroviral treatment (ART) experienced patients [poster 4552]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.
8. Viread (tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences, 2005.
9. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-6.
10. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-95.